Intraperitoneal injection of the FIPV S protein receptor-binding domain + membrane fusion complex resulted in a 82% reduction in viral load after 72 hours.
Targeting advantage: It has a 15-fold affinity for envelope viruses (such as feline herpesvirus FHV-1) and targets viruses first.
Immune cell activation: promotes NK cell perforin release (cat FIV infection T cell killing rate increases from 35% to 70%), induces M1 macrophage polarization, and enhances phagocytosis efficiency by 45%.